This Article Full Text (PDF) All Versions of this Article: 1352458509105426v1 15/8/951    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Carroll, W. Search for Related Content PubMed PubMed Citation Articles by Carroll, W. Pubmed/NCBI databases Medline Plus Health Information Multiple Sclerosis Social Bookmarking                         What's this?

Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit

Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia aansecwa{at}iinet.net.au

Background

The therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies provide long-term benefit.

Method and results

Long-term data from both registry studies and long-term follow-up studies, and efficacy treatment data were reviewed. Registry data show that the course of MS is predictable after a certain level of disability is reached, indicating that short-term efficacy data from randomized, controlled trials provide evidence of long-term benefit. Long-term studies of patients originally enrolled in pivotal randomized, controlled trials consistently show that delayed or discontinued treatment provides less benefit than continuous therapy. The 16-Year Long-Term Follow-Up Study of interferon beta-1b (IFNβ-1b; Betaferon®/Betaseron®) therapy had the highest ascertainment of long-term follow-up efforts of the pivotal trials, which led to the currently approved therapies. Disability scores at the start of treatment were predictive of their current disability scores. In addition, this 16-year study showed an excellent safety profile with no unexpected side effects to IFNβ-1b and a lower mortality rate after 16 years compared with those receiving placebo treatment during the pivotal study (6 deaths vs 20 deaths).

Conclusion

This article reviews the key data and provides recommendations for optimizing clinical studies in MS to demonstrate long-term patient benefit.

Key Words: immunomodulatory • interferon β • multiple sclerosis • long term

This version was published on August 1, 2009

Multiple Sclerosis, Vol. 15, No. 8, 951-958 (2009)
DOI: 10.1177/1352458509105426


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?